Advertisement

The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol

Tenofovir Nephrotoxicity

Here's a taste of what TheBody.com has to offer on this topic:
Ask the Experts

Tenofovir nephrotoxicity

Hii, I am an infectious disease doctor in Turkey. I would want to ask about my patient. She is 63 years old, with diabetes, osteopenia, ischemic cardiovascular disease, HIV positive for 9 years, but started to take treatment for the first time...
Benjamin Young, M.D., Ph.D.

Response from Benjamin Young, M.D., Ph.D.

Rocky Mountain CARES
Hello and thank you for posting from Turkey.It would seem that your patient has multiple risk factors for renal insufficiency-- but with a creatinine of 2.1 (?mg/dL), she has marked decrease in her glomerular filtration (or creatinine... Read more »

Lipoatrophy or Nephrotoxicity?

I've been hiv + for about 2 years, and I'm on treatment for 3 months. I'm using the... Read more »

Tenofovir and Hematuria (microscopic)

Hey Doc, always appreciate you advice!Have been on Tenofovir (as part of Atripla) for 8 years now,... Read more »
Articles
TheBodyPRO.com

Tenofovir-Containing Regimens May Not Be the Best Option for Patients With Abnormal Baseline Renal Function

Since the development of tenofovir (TDF, Viread) began, decreases in renal function among HIV-infected patients taking tenofovir-containing regimens have been reported. This was somewhat expected due to the renal clearance and metabolic pathway of... Read more »
U.S. Food and Drug Administration

Approval of Complera: Emtricitabine/Rilpivirine/Tenofovir DF Fixed-Dose Combination

On August 10, 2011, FDA approved Complera TM , a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera TM is one tablet, containing... Read more »
Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva (Efavirenz) and Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate)

New York, NY and Foster City, CA -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of... Read more »
TheBody.com

Stribild ("Quad") Recommended as Alternative First-Line HIV Treatment Regimen by U.S. Guidelines Panel

The newly approved four-in-one HIV drug Stribild (elvitegravir/cobicistat/FTC/tenofovir), also known as the "Quad," has gotten a tentative nod from the panel of experts that revises the official U.S. HIV treatment guidelines for adults and... Read more »